mTOR pathway activation drives lung cell senescence and emphysema
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Chronic obstructive pulmonary disease (COPD) is a highly prevalent and devastating condition for which no curative treatment is available. Exaggerated lung cell senescence may be a major pathogenic factor. Here, we investigated the potential role for mTOR signaling in lung cell senescence and alterations in COPD using lung tissue and derived cultured cells from patients with COPD and from age- and sex-matched control smokers. Cell senescence in COPD was linked to mTOR activation, and mTOR inhibition by low-dose rapamycin prevented cell senescence and inhibited the proinflammatory senescence-associated secretory phenotype. To explore whether mTOR activation was a causal pathogenic factor, we developed transgenic mice exhibiting mTOR overactivity in lung vascular cells or alveolar epithelial cells. In this model, mTOR activation was sufficient to induce lung cell senescence and to mimic COPD lung alterations, with the rapid development of lung emphysema, pulmonary hypertension, and inflammation. These findings support a causal relationship between mTOR activation, lung cell senescence, and lung alterations in COPD, thereby identifying the mTOR pathway as a potentially new therapeutic target in COPD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR Signaling in Growth Control and Disease
Laplante, M., & Sabatini, D. M. (2012) · Cell · doi:10.1016/j.cell.2012.03.017 · Cited by 8,509
mTOR Signaling in Growth, Metabolism, and Disease
Saxton, R. A., & Sabatini, D. M. (2017) · Cell · doi:10.1016/j.cell.2017.02.004 · Cited by 7,555
The senescence-associated secretory phenotype: the dark side of tumor suppression
Coppé, J.-P., Desprez, P.-Y., Krtolica, A., & Campisi, J. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102144 · Cited by 5,206
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Harrison, D. E., Strong, R., Sharp, Z. D., Nelson, J. F., Astle, C. M., Flurkey, K., Nadon, N. L., Wilkinson, J. E., Frenkel, K., Carter, C. S., et al. (2009) · Nature · doi:10.1038/nature08221 · Cited by 3,766 · cited 1×
“Rapamycin inhibits mTOR activity and is one of the few drugs capable of prolonging life in many species (18).”
Cellular senescence: from physiology to pathology
Muñoz-Espín, D., & Serrano, M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3823 · Cited by 2,818
Chemokine signaling via the CXCR2 receptor reinforces senescence
Acosta, J. C., O'Loghlen, A., Banito, A., Guijarro, M. V., Augert, A., Raguz, S., Fumagalli, M., Da Costa, M., Brown, C., Popov, N., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.038 · Cited by 1,801 · cited 1×
“The inflammatory cytokines IL-6, IL-8, and IL-1 β released as part of the SASP are well-known inducers of cell senescence (38, 39).”
Self-citationInflammatory networks during cellular senescence: causes and consequences.
Freund, A., Orjalo, A. V., Desprez, P.-Y., & Campisi, J. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.03.003 · Cited by 1,354
Laberge, R.-M., Sun, Y., Orjalo, A. V., Patil, C. K., Freund, A., Zhou, L., Curran, S. C., Davalos, A. R., Wilson-Edell, K. A., Liu, S., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3195 · Cited by 1,160 · cited 2×
“in senescent human cells by acting on the translation of IL-1β, a master regulator of the NF-κB transcription factor (40).”
Armanios, M., & Blackburn, E. H. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3246 · Cited by 982
Kume, S., Uzu, T., Horiike, K., Chin-Kanasaki, M., Isshiki, K., Araki, S.-I., Sugimoto, T., Haneda, M., Kashiwagi, A., & Koya, D. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41376 · Cited by 640 · cited 1×
“SIRT1 mediates the deacetylation of ATG proteins and transcription factors, including the FOXO3 family, and stimulates autophagy (47, 48).”
Research works printed but not linked: 36
- 10.1016/S0140-6736(11)60990-2 · DOI · Paper page
- 10.1183/09031936.04.00014304 · DOI · Paper page
- 10.1164/rccm.201209-1665OC · DOI · Paper page
- 10.1164/rccm.200912-1843CC · DOI · Paper page
- 10.1016/j.pharmthera.2015.06.007 · DOI
- 10.1038/35106045 · DOI · Paper page
- 10.1016/0014-4827(65)90211-9 · DOI · Paper page
- 10.1164/rccm.201105-0802OC · DOI · Paper page
- 10.1016/j.tibs.2013.01.004 · DOI · Paper page
- 10.1016/j.ccr.2008.11.003 · DOI · Paper page
- 10.1016/j.cell.2006.01.016 · DOI · Paper page
- 10.1074/jbc.R109.094003 · DOI · Paper page
- Ferrand, 2015, Screening of a kinase library reveals novel pro-senescence kinases and their common NF-κB-dependent transcriptional program, Aging (Albany NY), 7, 986, 10.18632/aging.100845 · DOI · Paper page
- 10.1165/rcmb.2015-0339OC · DOI
- 10.1002/dvg.20367 · DOI · Paper page
- 10.1073/pnas.152238499 · DOI · Paper page
- 10.1016/j.trecan.2016.03.008 · DOI · Paper page
- 10.1161/CIRCULATIONAHA.110.973750 · DOI
- 10.1161/ATVBAHA.113.302302 · doi:10.1161/atvbaha.113.302302
- 10.1161/CIRCULATIONAHA.113.004581 · DOI · Paper page
- 10.1164/rccm.200809-1398OC · DOI · Paper page
- 10.1165/rcmb.2003-0290OC · DOI · Paper page
- 10.1164/rccm.201503-0593OC · DOI
- 10.1164/rccm.200906-0937OC · DOI · Paper page
- 10.1038/nm.2157 · DOI · Paper page
- Liebow, 1959, Pulmonary emphysema with special reference to vascular changes, Am Rev Respir Dis, 80, 67
- 10.1016/j.cell.2011.08.035 · DOI · Paper page
- 10.1152/ajplung.00047.2015 · DOI
- 10.1038/cr.2013.166 · DOI · Paper page
- 10.1073/pnas.0712145105 · DOI · Paper page
- 10.1165/rcmb.2013-0023OC · DOI
- Jarrard, 1998, MUC1 is a novel marker for the type II pneumocyte lineage during lung carcinogenesis, Cancer Res, 58, 5582
- Vindrieux, 2014, Repression of PLA2R1 by c-MYC and HIF-2alpha promotes cancer growth, Oncotarget, 5, 1004, 10.18632/oncotarget.1681 · DOI · Paper page
- 10.1161/CIRCULATIONAHA.114.013258 · DOI
- Drummond, 2017, Combined Effects of in Utero and Adolescent Tobacco Smoke Exposure on Lung Function in C57Bl/6J Mice, Environ Health Perspect, 125, 392, 10.1289/EHP54 · DOI
- 10.1152/japplphysiol.01100.2009 · DOI · Paper page
Cited by
Cellular senescence and senolytics: the path to the clinic
Chaib, S., Tchkonia, T., & Kirkland, J. L. (2022) · Nature Medicine · doi:10.1038/s41591-022-01923-y · Cited by 1,134
Cellular Senescence as a Mechanism and Target in Chronic Lung Diseases
Barnes, P. J., Baker, J., & Donnelly, L. E. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201810-1975tr · Cited by 555
Update on the Pathogenesis of Chronic Obstructive Pulmonary Disease
Agustí, A., & Hogg, J. C. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1900475 · Cited by 551
Effect of rapamycin on aging and age-related diseases—past and future
Selvarani, R., Mohammed, S., & Richardson, A. (2021) · GeroScience · doi:10.1007/s11357-020-00274-1 · Cited by 290
Oxidative Stress in Chronic Obstructive Pulmonary Disease
Barnes, P. J. (2022) · Antioxidants · doi:10.3390/antiox11050965 · Cited by 281
Skeletal Aging and Osteoporosis: Mechanisms and Therapeutics
Chandra, A., & Rajawat, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073553 · Cited by 264
Mechanisms of airway epithelial injury and abnormal repair in asthma and COPD
Raby, K. L., Michaeloudes, C., Tonkin, J., Chung, K. F., & Bhavsar, P. K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1201658 · Cited by 260
Han, Y., & Kim, S. Y. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-022-00906-w · Cited by 201
Cellular Metabolism in Lung Health and Disease
Liu, G., & Summer, R. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114640 · Cited by 157
Cellular senescence impairs the reversibility of pulmonary arterial hypertension
van der Feen, D. E., Bossers, G. P. L., Hagdorn, Q. A. J., Moonen, J.-R., Kurakula, K., Szulcek, R., Chappell, J., Vallania, F., Donato, M., Kok, K., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw4974 · Cited by 150
Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression
Born, E., Lipskaia, L., Breau, M., Houssaini, A., Beaulieu, D., Marcos, E., Pierre, R., Do Cruzeiro, M., Lefevre, M., Derumeaux, G., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.058794 · Cited by 148
Self-citationThe Role of Rapamycin in Healthspan Extension via the Delay of Organ Aging
Zhang, Y., Zhang, J., & Wang, S. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101376 · Cited by 92
Rapamycin improves healthspan but not inflammaging in nfκb1−/− mice
Correia‐Melo, C., Birch, J., Fielder, E., Rahmatika, D., Taylor, J., Chapman, J., Lagnado, A., Carroll, B. M., Miwa, S., Richardson, G., et al. (2019) · Aging Cell · doi:10.1111/acel.12882 · Cited by 77
Xiaofei, Y., Tingting, L., Xuan, W., & Zhiyi, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1043474 · Cited by 31
Metadata
- Authors
- Houssaini, A., Breau, M., Kebe, K., Abid, S., Marcos, E., Lipskaia, L., Rideau, D., Parpaleix, A., Huang, J., Amsellem, V., Vienney, N., Validire, P., Maitre, B., Attwe, A., Lukas, C., Vindrieux, D., Boczkowski, J., Derumeaux, G., Pende, M., Bernard, D., Meiners, S., & Adnot, S.
- Venue
- JCI Insight
- Published
- 2018-02-08
- Volume
- 3
- Issue
- 3
- ISSN
- 2379-3708 (ISSN-L)
- OpenAlex
- W2787112610
- Cited by
- 220
- References
- 20
- FWCI
- 14.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.